ALK and angioimmunoblastic T-cell lymphoma: With a median follow up of 57 months (range: 2.3–192 months), 13 patients (4 PTCL-NOS, 1 AITL, 4 ALK+ ALCL, 2 ALK-ALCL, and 2 ENKL) experienced CNS relapse, and 309 patients (52%) died without CNS relapse.